You searched for Switzerland - Page 29 of 39

News and Trends 22 Aug 2022

Drug to treat rare kidney disease to be reviewed by EMA

The European Medicines Agency (EMA) has agreed to review a conditional marketing authorization (CMA) application for a drug to treat a rare kidney disorder. The news was announced today (August…

August 22, 2022 - 3 minutesmins - By Liza Laws

Interview 30 May 2019

Taking Inspiration from Plants to Prevent Mold from Ruining Crops

Olga Dubey founded the Swiss startup Agrosustain with the intention to bring forth a natural alternative to chemical pesticides against mold. She shares how it all started and her company’s…

May 30, 2019 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 May 2017

Roche’s Checkpoint Inhibitor Misfires in Late-Stage Trials

Roche’s drug tecentriq just failed a late-stage Phase III study in bladder cancer, raising questions about its future as an anticipated blockbuster. Roche and Genentech have been pushing their checkpoint…

May 10, 2017 - 3 minutesmins - By Melanie De Almeida

CRISPR Cas9 antimicrobial peptide antibiotic resistance

News and Trends 26 Feb 2019

Swiss Scientists Find ‘Silver Bullet’ Against Bacterial Infections

Using the gene editing tool CRISPR-Cas9, researchers in Lausanne have uncovered antimicrobial molecules in the fruit fly that can selectively kill certain bacteria. This could lead to new therapeutics combatting…

February 26, 2019 - 3 minutesmins - By Jonathan Smith

pneumonia lungs polyphor antibiotic resistance

News and Trends 10 May 2019

Swiss Biotech Halts Pneumonia Antibiotic Trial After Patient Safety Scare

Polyphor has temporarily halted two phase III trials of an antibiotic treating pneumonia, after an unexpectedly high number of patients reported kidney problems in one of the trials. The phase…

May 10, 2019 - 3 minutesmins - By Jonathan Smith

boehringer ingelheim cancer vaccine amal therapeutics

News and Trends 16 Jul 2019

Boehringer Ingelheim Acquires Cancer Vaccine Biotech in €325M Deal

The German giant Boehringer Ingelheim has acquired the Swiss company AMAL Therapeutics and its cancer vaccine technology in a deal worth up to €325M. The deal includes €225M in upfront…

July 16, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 16 Apr 2016

First Euronext Biotech IPO of 2016 is Swiss, and for Multiple Sclerosis!

We last wrote about GeNeuro in January, when they announced the launch of an IPO for their Multiple Sclerosis phase IIb trial. Now, as of yesterday they are listed on…

April 16, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 4 Nov 2022

A new weapon against antibiotic-resistant bacteria?

Is edoxudine, an anti-herpes molecule discovered in the 60s, effective against Klebsiella pneumoniae, a common bacterium in hospitals? The excessive use of antibiotics has pushed bacteria to develop resistance mechanisms…

November 4, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 20 Jun 2017

Novartis Tops Ophthalmology Blockbuster Eylea in Phase III Trials

Bayer’s and Regeneron’s blockbuster Eylea could be facing serious competition, as Novartis boasts with positive Phase III results for AMD. Novartis has been struggling on the age-related macular degeneration (AMD)…

June 20, 2017 - 2 minutesmins - By Melanie De Almeida

AMAL Therapeutics Cancer Vaccine Series B

News and Trends 5 Sep 2017

Swiss Biotech Raises €8M in First Closing of Series B to Develop Cancer Vaccines

AMAL Therapeutics has raised €8M to push its colorectal cancer vaccine ATP128 into clinical trials and keep developing its tumor vaccine pipeline. AMAL Therapeutics, a young biotech based in Geneva,…

September 5, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 9 Dec 2015

Squeezing Cells: A Revolutionary Cancer Drug Delivery Platform for €455M?

The MIT spin-off SQZ Biotech has an invention (Cell SQueeZe) which could make vector drug delivery in Cancer a thing of the past… Roche thinks so too, and has now…

December 9, 2015 - 3 minutesmins - By Dani Bancroft

bc platforms biogen microsoft multiple sclerosis

News and Trends 16 Oct 2017

Swiss Genomics Firm, Biogen and Microsoft Team Up to Treat Multiple Sclerosis

BC Platforms and Microsoft will be working with Biogen and the Accelerated Cure Project to study the genetics of multiple sclerosis and accelerate research. The Swiss firm BC Platforms has…

October 16, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Search Results for: Switzerland

Drug to treat rare kidney disease to be reviewed by EMA

Taking Inspiration from Plants to Prevent Mold from Ruining Crops

Roche’s Checkpoint Inhibitor Misfires in Late-Stage Trials

Swiss Scientists Find ‘Silver Bullet’ Against Bacterial Infections

Swiss Biotech Halts Pneumonia Antibiotic Trial After Patient Safety Scare

Boehringer Ingelheim Acquires Cancer Vaccine Biotech in €325M Deal

First Euronext Biotech IPO of 2016 is Swiss, and for Multiple Sclerosis!

A new weapon against antibiotic-resistant bacteria?

Novartis Tops Ophthalmology Blockbuster Eylea in Phase III Trials

Swiss Biotech Raises €8M in First Closing of Series B to Develop Cancer Vaccines

Squeezing Cells: A Revolutionary Cancer Drug Delivery Platform for €455M?

Swiss Genomics Firm, Biogen and Microsoft Team Up to Treat Multiple Sclerosis

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!